JHURX Mutual Fund

NAV$48.95

Fund Essentials - as of Jan 31, 2026

Net Assets
$4M
Expense Ratio
1.24%
Dividend Yield (Current)
0.45%
Holdings
94
Inception Date
Jul 31, 2017
Fund Family
J.P. Morgan Asset Management
Investment Style
••••••••••
Asset Class
••••••••••
Legal Structure
••••••••••
Dividend Frequency
Annually

Performance

YTD+29.40%
1 Year+57.87%
3 Year+24.28%
5 Year+5.55%

Asset Allocation

Stocks: 98.93%
Cash: 1.07%

Top Holdings

View All →
TickerNameWeight
2330:TWTaiwan Semiconductor Manufacturing Co. Ltd.10.17%
000660:KRSk Hynix Inc Common Stock KRW 50006.95%
0700:HKTencent Holdings Ltd5.81%
005930:KRSamsung Electronics (Equity)3.97%
TSM:TWTaiwan Semiconductor - Adr3.18%
Top 10 Concentration: 41.92%Report Date: Jan 31, 2026
Download all 94 holdings for JHURX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
0.45%
Frequency
Annually
Latest Distribution
$0.11
-

Peer Comparison

Benchmark
••••••••••
Outperforming by ••••%
Ranked #••• of •,••• funds
This Mutual Fund
+••.••%
Peer Avg
+••.••%
Premium Feature
Sign in to unlock peer comparison, category rankings and more

JHURX Mutual Fund Overview

JHURX Mutual Fund (JPMorgan Emerging Markets Equity Fund Class R3) is managed by J.P. Morgan Asset Management with $3.8M in net assets. JHURX expense ratio is 1.24%, holding 94 positions across sectors including Unknown, Communication Services, Consumer Discretionary. Inception date: 2017-07-31.

JHURX performance shows a YTD return of 29.40%. The 1-year return is 57.87% and the 5-year return is 5.55%. JHURX dividend yield stands at 0.45%, paid annually.

JHURX top holdings include Taiwan Semiconductor Manufacturing Co. Ltd. (10.2%), Sk Hynix Inc Common Stock KRW 5000 (7.0%), Tencent Holdings Ltd (5.8%), Samsung Electronics (Equity) (4.0%), Taiwan Semiconductor - Adr (3.2%). View all JHURX holdings, sector breakdown, or dividend history.

JHURX can be compared against other funds using the overlap calculator or side-by-side comparison tool. JHURX alternatives are available via the screener, along with tax-loss harvesting opportunities.